Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30050042 | 1.00 | EGFR (0.54) | EGFRERBB2 | |
| SCHEMBL30049976 | 0.89 | ERBB2 (0.47) | EGFRERBB2 | |
| SCHEMBL30049707 | 0.88 | EGFR (0.47) | EGFRERBB2 | |
| SCHEMBL24809518 | 0.88 | EGFR (0.47) | EGFRERBB2 | |
| SCHEMBL30050551 | 0.87 | EGFR (0.51) | EGFRERBB2 | |
| SCHEMBL24809043 | 0.87 | EGFR (0.51) | EGFRERBB2 | |
| SCHEMBL24807692 | 0.86 | ERBB2 (0.54) | EGFRERBB2 | |
| Hydrochloric Acid SCHEMBL30050753 | 0.84 | EGFR (0.40) | EGFRERBB2 | |
| SCHEMBL24809491 | 0.84 | ERBB2 (0.54) | EGFRERBB2 | |
| SCHEMBL24809511 | 0.84 | ERBB2 (0.54) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022269531-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.